{"id":4015,"date":"2018-10-19T16:36:27","date_gmt":"2018-10-19T14:36:27","guid":{"rendered":"https:\/\/thesmartcityjournal.cibeles.net\/sin-categorizar\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama\/"},"modified":"2018-10-19T16:36:27","modified_gmt":"2018-10-19T14:36:27","slug":"la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama","status":"publish","type":"post","link":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama","title":{"rendered":"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama"},"content":{"rendered":"<p align=\"JUSTIFY\"><span style=\"font-family: verdana, geneva, sans-serif;font-size: 10pt;color: #000000\"><span lang=\"es-ES\">La tasa de supervivencia a los cinco a\u00f1os se acerca ya al 90% en nuestro pa\u00eds<\/p>\n<p><\/span><span lang=\"es-ES\">El c\u00e1ncer de mama es una de las enfermedades que engloba mayores esfuerzos en materia de I+D por parte de las compa\u00f1\u00edas farmac\u00e9uticas, que tienen en distintas fases de investigaci\u00f3n cl\u00ednica un total de 169 nuevos medicamentos a escala global contra este tumor. Se trata del tumor m\u00e1s frecuente en mujeres (si bien afecta tambi\u00e9n a los hombres, que padecen el 1 por ciento de los casos), seg\u00fan los \u00faltimos datos hechos p\u00fablicos por\u00a0<\/span><a style=\"color: #000000\" href=\"https:\/\/www.phrma.org\/\"><span lang=\"es-ES\">Phrma<\/span><\/a><span lang=\"es-ES\">, la asociaci\u00f3n estadounidense de la industria farmac\u00e9utica innovadora.<\/span><\/span><\/p>\n<p lang=\"es-ES\" align=\"JUSTIFY\"><span style=\"font-family: verdana, geneva, sans-serif;font-size: 10pt;color: #000000\"><span lang=\"es-ES\">S\u00f3lo en Espa\u00f1a se han registrado, en los \u00faltimos cinco a\u00f1os, un total de 195 ensayos cl\u00ednicos centrados en esta enfermedad, de la que se contabilizan m\u00e1s de 26.000 nuevos casos al a\u00f1o en nuestro pa\u00eds, seg\u00fan consta en el\u00a0<\/span><a style=\"color: #000000\" href=\"https:\/\/reec.aemps.es\/reec\/public\/web.html\"><span lang=\"es-ES\">Registro Espa\u00f1ol de Ensayos Cl\u00ednicos (REEC)<\/span><\/a><span lang=\"es-ES\">. En el 90% de los casos estos ensayos han sido impulsados directamente por la industria farmac\u00e9utica.<\/span><\/span><\/p>\n<p lang=\"es-ES\" align=\"JUSTIFY\"><span style=\"font-family: verdana, geneva, sans-serif;font-size: 10pt;color: #000000\"><span lang=\"es-ES\">El mejor conocimiento de la biolog\u00eda del tumor y de la respuesta inmune ha permitido identificar nuevas dianas terap\u00e9uticas y desarrollar medicamentos espec\u00edficamente dirigidos contra ellas, m\u00e1s precisos, m\u00e1s eficaces y con menores efectos secundarios, cambiando el tratamiento de la enfermedad y su pron\u00f3stico. Junto a ello, las nuevas t\u00e9cnicas diagn\u00f3sticas -como la biopsia l\u00edquida-, los actuales abordajes quir\u00fargicos, el impulso a los programas de prevenci\u00f3n y de detecci\u00f3n precoz y la implicaci\u00f3n creciente de los pacientes est\u00e1n conduciendo a que el c\u00e1ncer de mama se convierta en uno de los tumores con mejor pron\u00f3stico, cuando se aborda en fases tempranas.<\/span><\/span><\/p>\n<p align=\"JUSTIFY\"><span style=\"font-family: verdana, geneva, sans-serif;font-size: 10pt;color: #000000\"><span lang=\"es-ES\">As\u00ed, las tasas de supervivencia de esta enfermedad han ido aumentando en las \u00faltimas d\u00e9cadas en Espa\u00f1a, pasando del 70% de supervivencia a los cinco a\u00f1os para pacientes diagnosticadas a finales de los a\u00f1os 80 al 80,3% en el periodo 1995-1999 y al 82,8% en 2000-2007, seg\u00fan refleja la base de datos\u00a0<\/span><a style=\"color: #000000\" href=\"http:\/\/www.eurocare.it\/\"><span lang=\"es-ES\">Eurocare<\/span><\/a><span lang=\"es-ES\">.<\/span><\/span><\/p>\n<p lang=\"es-ES\" align=\"JUSTIFY\"><span style=\"font-family: verdana, geneva, sans-serif;font-size: 10pt;color: #000000\"><span lang=\"es-ES\">En la actualidad cerca del 90% de las pacientes contin\u00faan libres de enfermedad cinco a\u00f1os despu\u00e9s del diagn\u00f3stico en Espa\u00f1a, seg\u00fan la\u00a0<\/span><a style=\"color: #000000\" href=\"https:\/\/seom.org\/seomcms\/images\/stories\/recursos\/Las_Cifras_del_cancer_en_Espana2018.pdf\"><span lang=\"es-ES\">Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM)<\/span><\/a><span lang=\"es-ES\">, que destacaba recientemente que en los casos de enfermedad avanzada \u201cexisten f\u00e1rmacos nuevos m\u00e1s selectivos y menos t\u00f3xicos que, asociados a tratamientos cl\u00e1sicos como quimioterapia u hormonoterapia, permiten incrementar la supervivencia y mejorar la calidad de vida de una manera muy significativa\u201d.<\/span><\/span><\/p>\n<p align=\"JUSTIFY\">\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La tasa de supervivencia a los cinco a\u00f1os se acerca ya al 90% en nuestro pa\u00edsEl c\u00e1ncer de mama es una de las enfermedades que engloba mayores esfuerzos en materia de I+D por parte de las compa\u00f1\u00edas farmac\u00e9uticas, que tienen en distintas fases de investigaci\u00f3n cl\u00ednica un total de 169 nuevos medicamentos a escala global\u2026<\/p>\n","protected":false},"author":2,"featured_media":4014,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_scj_primary_category_id":87,"_scj_featured":false,"_scj_featured_from":"","_scj_featured_until":"","_scj_featured_order":0,"_scj_visibility_class":"current","_scj_layout_family":"standard","_scj_article_style":"","_scj_display_overrides":[],"_scj_intro_image_id":4014,"_scj_intro_alt":"","_scj_intro_caption":"","_scj_intro_class":"","_scj_intro_float":"","_scj_full_image_id":4014,"_scj_full_alt":"","_scj_full_caption":"","_scj_full_class":"","_scj_full_float":"","_scj_media_type":"","_scj_media_provider":"","_scj_media_external_id":"","_scj_media_url":"","_scj_media_poster_id":0,"_scj_media_width":0,"_scj_media_height":0,"_scj_media_aspect_ratio":"","_scj_media_description":"","_scj_gallery_items":[],"_scj_related_post_ids":[],"_scj_additional_authors":[],"scj_layout_family":"standard","scj_media_provider":"","scj_media_url":"","scj_full_caption":"","footnotes":""},"categories":[87],"tags":[],"class_list":["post-4015","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-smart-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama - thesmartcityjournal.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama - thesmartcityjournal.com\" \/>\n<meta property=\"og:description\" content=\"La tasa de supervivencia a los cinco a\u00f1os se acerca ya al 90% en nuestro pa\u00edsEl c\u00e1ncer de mama es una de las enfermedades que engloba mayores esfuerzos en materia de I+D por parte de las compa\u00f1\u00edas farmac\u00e9uticas, que tienen en distintas fases de investigaci\u00f3n cl\u00ednica un total de 169 nuevos medicamentos a escala global\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama\" \/>\n<meta property=\"og:site_name\" content=\"thesmartcityjournal.com\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/thesmartcityjournal\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-19T14:36:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.thesmartcityjournal.com\/wp-content\/uploads\/2018\/10\/cncer-mama-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1777\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Redacci\u00f3n de The Smart City Journal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SmartCityJour_\" \/>\n<meta name=\"twitter:site\" content=\"@SmartCityJour_\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Redacci\u00f3n de The Smart City Journal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama\"},\"author\":{\"@type\":\"Organization\",\"name\":\"Redacci\u00f3n de The Smart City Journal\",\"url\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/author\\\/smart-city\"},\"headline\":\"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama\",\"datePublished\":\"2018-10-19T14:36:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama\"},\"wordCount\":451,\"publisher\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/cncer-mama-scaled.jpg\",\"articleSection\":[\"Smart Health\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama\",\"url\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama\",\"name\":\"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama - thesmartcityjournal.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/cncer-mama-scaled.jpg\",\"datePublished\":\"2018-10-19T14:36:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#primaryimage\",\"url\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/cncer-mama-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/cncer-mama-scaled.jpg\",\"width\":2560,\"height\":1777},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/smart-health\\\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/\",\"name\":\"thesmartcityjournal.com\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/#organization\",\"name\":\"thesmartcityjournal.com\",\"url\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo-smart-city-journal-1.png\",\"contentUrl\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo-smart-city-journal-1.png\",\"width\":346,\"height\":91,\"caption\":\"thesmartcityjournal.com\"},\"image\":{\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/thesmartcityjournal\",\"https:\\\/\\\/x.com\\\/SmartCityJour_\",\"https:\\\/\\\/www.instagram.com\\\/thesmartcityjournal_\\\/\",\"https:\\\/\\\/www.tiktok.com\\\/@thesmartcityjournal\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/the-smart-city-journal\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCIPTMzK206pVFxMNjO7SSxw\"]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/#\\\/schema\\\/person\\\/39c9da1aeac1b5c2d179ef9e4e293cf4\",\"name\":\"Redacci\u00f3n de The Smart City Journal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/?s=96&d=mm&r=g\",\"caption\":\"Redacci\u00f3n de The Smart City Journal\"},\"description\":\"Equipo de redacci\u00f3n de The Smart City Journal.\",\"url\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es\\\/author\\\/smart-city\"},{\"@type\":[\"Organization\",\"NewsMediaOrganization\"],\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es#organization\"},{\"@type\":\"SiteNavigationElement\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es#site-navigation\",\"cssSelector\":[\".cib-main-menu\"]},{\"@type\":\"WPHeader\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es#header\",\"cssSelector\":[\".cib-header\"]},{\"@type\":\"WPFooter\",\"@id\":\"https:\\\/\\\/www.thesmartcityjournal.com\\\/es#footer\",\"cssSelector\":[\".cib-footer\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama - thesmartcityjournal.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama","og_locale":"es_ES","og_type":"article","og_title":"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama - thesmartcityjournal.com","og_description":"La tasa de supervivencia a los cinco a\u00f1os se acerca ya al 90% en nuestro pa\u00edsEl c\u00e1ncer de mama es una de las enfermedades que engloba mayores esfuerzos en materia de I+D por parte de las compa\u00f1\u00edas farmac\u00e9uticas, que tienen en distintas fases de investigaci\u00f3n cl\u00ednica un total de 169 nuevos medicamentos a escala global\u2026","og_url":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama","og_site_name":"thesmartcityjournal.com","article_publisher":"https:\/\/www.facebook.com\/thesmartcityjournal","article_published_time":"2018-10-19T14:36:27+00:00","og_image":[{"width":2560,"height":1777,"url":"https:\/\/www.thesmartcityjournal.com\/wp-content\/uploads\/2018\/10\/cncer-mama-scaled.jpg","type":"image\/jpeg"}],"author":"Redacci\u00f3n de The Smart City Journal","twitter_card":"summary_large_image","twitter_creator":"@SmartCityJour_","twitter_site":"@SmartCityJour_","twitter_misc":{"Escrito por":"Redacci\u00f3n de The Smart City Journal","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#article","isPartOf":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama"},"author":{"@type":"Organization","name":"Redacci\u00f3n de The Smart City Journal","url":"https:\/\/www.thesmartcityjournal.com\/es\/author\/smart-city"},"headline":"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama","datePublished":"2018-10-19T14:36:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama"},"wordCount":451,"publisher":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/#organization"},"image":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#primaryimage"},"thumbnailUrl":"https:\/\/www.thesmartcityjournal.com\/wp-content\/uploads\/2018\/10\/cncer-mama-scaled.jpg","articleSection":["Smart Health"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama","url":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama","name":"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama - thesmartcityjournal.com","isPartOf":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#primaryimage"},"image":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#primaryimage"},"thumbnailUrl":"https:\/\/www.thesmartcityjournal.com\/wp-content\/uploads\/2018\/10\/cncer-mama-scaled.jpg","datePublished":"2018-10-19T14:36:27+00:00","breadcrumb":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#primaryimage","url":"https:\/\/www.thesmartcityjournal.com\/wp-content\/uploads\/2018\/10\/cncer-mama-scaled.jpg","contentUrl":"https:\/\/www.thesmartcityjournal.com\/wp-content\/uploads\/2018\/10\/cncer-mama-scaled.jpg","width":2560,"height":1777},{"@type":"BreadcrumbList","@id":"https:\/\/www.thesmartcityjournal.com\/es\/smart-health\/la-industria-farmaceutica-tiene-en-fase-de-i-d-169-nuevos-medicamentos-contra-el-cancer-de-mama#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.thesmartcityjournal.com\/es"},{"@type":"ListItem","position":2,"name":"La industria farmac\u00e9utica tiene en fase de I+D 169 nuevos medicamentos contra el c\u00e1ncer de mama"}]},{"@type":"WebSite","@id":"https:\/\/www.thesmartcityjournal.com\/es\/#website","url":"https:\/\/www.thesmartcityjournal.com\/es\/","name":"thesmartcityjournal.com","description":"","publisher":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.thesmartcityjournal.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.thesmartcityjournal.com\/es\/#organization","name":"thesmartcityjournal.com","url":"https:\/\/www.thesmartcityjournal.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.thesmartcityjournal.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.thesmartcityjournal.com\/wp-content\/uploads\/2026\/09\/logo-smart-city-journal-1.png","contentUrl":"https:\/\/www.thesmartcityjournal.com\/wp-content\/uploads\/2026\/09\/logo-smart-city-journal-1.png","width":346,"height":91,"caption":"thesmartcityjournal.com"},"image":{"@id":"https:\/\/www.thesmartcityjournal.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/thesmartcityjournal","https:\/\/x.com\/SmartCityJour_","https:\/\/www.instagram.com\/thesmartcityjournal_\/","https:\/\/www.tiktok.com\/@thesmartcityjournal","https:\/\/www.linkedin.com\/company\/the-smart-city-journal\/","https:\/\/www.youtube.com\/channel\/UCIPTMzK206pVFxMNjO7SSxw"]},{"@type":"Organization","@id":"https:\/\/www.thesmartcityjournal.com\/es\/#\/schema\/person\/39c9da1aeac1b5c2d179ef9e4e293cf4","name":"Redacci\u00f3n de The Smart City Journal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&r=g","caption":"Redacci\u00f3n de The Smart City Journal"},"description":"Equipo de redacci\u00f3n de The Smart City Journal.","url":"https:\/\/www.thesmartcityjournal.com\/es\/author\/smart-city"},{"@type":["Organization","NewsMediaOrganization"],"@id":"https:\/\/www.thesmartcityjournal.com\/es#organization"},{"@type":"SiteNavigationElement","@id":"https:\/\/www.thesmartcityjournal.com\/es#site-navigation","cssSelector":[".cib-main-menu"]},{"@type":"WPHeader","@id":"https:\/\/www.thesmartcityjournal.com\/es#header","cssSelector":[".cib-header"]},{"@type":"WPFooter","@id":"https:\/\/www.thesmartcityjournal.com\/es#footer","cssSelector":[".cib-footer"]}]}},"_links":{"self":[{"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/posts\/4015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/comments?post=4015"}],"version-history":[{"count":0,"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/posts\/4015\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/media\/4014"}],"wp:attachment":[{"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/media?parent=4015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/categories?post=4015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.thesmartcityjournal.com\/es\/wp-json\/wp\/v2\/tags?post=4015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}